ישראל - עברית - Ministry of Health

padagis israel pharmaceuticals ltd, israel - testosterone - ג'ל - testosterone 25 mg/dose - testosterone - testosterone - testosterone replacement therapy for males hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

ישראל - עברית - Ministry of Health

padagis israel pharmaceuticals ltd, israel - testosterone - ג'ל - testosterone 50 mg/dose - testosterone and estrogen - testosterone and estrogen - testosterone replacement therapy for males hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

ישראל - עברית - Ministry of Health

cts ltd - testosterone - ג'ל - testosterone 0.05 mg/sachet - testosterone - testosterone - testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

ישראל - עברית - Ministry of Health

bayer israel ltd - testosterone undecanoate - תמיסה להזרקה - testosterone undecanoate 250 mg/ml - testosterone - testosterone - testosterone replacement therpay in primary and secondary male hypogonadism.

ישראל - עברית - Ministry of Health

bayer israel ltd - testosterone enantate - תמיסה שומנית להזרקה - testosterone enantate 250 mg/ml - testosterone - testosterone - testosterone replacement therapy in male hypogonadism, in cases where testosterone deficiency has been confirmed on the basis of clinical and lboratory evidence.inducing puberty in boys with delayed puberty (pubertas tarda).

ישראל - עברית - Ministry of Health

cts ltd - testosterone - ג'ל - testosterone 0.05 g/dose - testosterone

ישראל - עברית - Ministry of Health

cts ltd - testosterone - ג'ל - testosterone 0.05 g/dose - testosterone

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - testosterone undecanoate 40 mg - capsules - testosterone - testosteronic replacement therapy in male hydrogonadal disorders.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and nor

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal